Loader

Pathways

PathWhiz ID Pathway Meta Data

PW124475

Pw124475 View Pathway
drug action

Valproic Acid i.e. Sodium Valproate (New: Drug Action)

Homo sapiens
Sodium valproate, also known as valproic acid, is a fatty acid derivative and anticonvulsant first synthesized in 1881-1882 from an analogue derived from the Valerian herb; however, its mechanism of action is not fully elucidated (yet). Traditionally, researchers and clinicians consider it to be an anticonvulsant due to its effects in the brain: it blocks voltage-gated sodium channels and potentiates gamma-aminobutyric acid (GABA) activity. Over the past centuries, investigations show valproate may also have neuroprotective, anti-manic, and anti-migraine effects. It is a compound of interest in the field of oncology for its anti-proliferative effects and has undergone some clinical trials. Currently, valproate is indicated for use as a monotherapy or adjunct medication in seizure management, for migraine prophylaxis, and for mitigation of acute mania associated with bipolar disorder. Off-label, clinicians may use valproate to manage bipolar disorder or for emergency treatment of status epilepticus. Valproate can be administered orally, in which case it undergoes hepatic first-pass metabolism to enter the bloodstream ___________________ https://go.drugbank.com/drugs/DB00313

PW144440

Pw144440 View Pathway
drug action

Valproic acid Drug Metabolism Action Pathway

Homo sapiens

PW124164

Pw124164 View Pathway
drug action

Valproic Acid (Drug Action) - New - DISCARD

Homo sapiens

PW124228

Pw124228 View Pathway
drug action

Valproate w/ Template (New) Drug Action Action Pathway

Homo sapiens

PW146698

Pw146698 View Pathway
drug action

Valproate bismuth Drug Metabolism Action Pathway

Homo sapiens

PW132221

Pw132221 View Pathway
metabolic

Valproate bismuth Drug Metabolism

Homo sapiens
Valproate bismuth is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Valproate bismuth passes through the liver and is then excreted from the body mainly through the kidney.

PW064779

Pw064779 View Pathway
metabolic

Valine,leucine,isoleucine degradation

Homo sapiens

PW088346

Pw088346 View Pathway
metabolic

Valine, Leucine, and Isoleucine Degradation

Rattus norvegicus
Valine, isoleuciine, and leucine are essential amino acids and are identified as the branched-chain amino acids (BCAAs). The catabolism of all three amino acids starts in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with α-ketoglutarate as the amine acceptor. As a result, three different α-keto acids are produced and are oxidized using a common branched-chain α-keto acid dehydrogenase (BCKD), yielding the three different CoA derivatives. Isovaleryl-CoA is produced from leucine by these two reactions, alpha-methylbutyryl-CoA from isoleucine, and isobutyryl-CoA from valine. These acyl-CoA’s undergo dehydrogenation, catalyzed by three different but related enzymes, and the breakdown pathways then diverge. Leucine is ultimately converted into acetyl-CoA and acetoacetate; isoleucine into acetyl-CoA and succinyl-CoA; and valine into propionyl-CoA (and subsequently succinyl-CoA). Under fasting conditions, substantial amounts of all three amino acids are generated by protein breakdown. In muscle, the final products of leucine, isoleucine, and valine catabolism can be fully oxidized via the citric acid cycle; in the liver, they can be directed toward the synthesis of ketone bodies (acetoacetate and acetyl-CoA) and glucose (succinyl-CoA). Because isoleucine catabolism terminates with the production of acetyl-CoA and propionyl-CoA, it is both glucogenic and ketogenic. Because leucine gives rise to acetyl-CoA and acetoacetyl-CoA, it is classified as strictly ketogenic.

PW088253

Pw088253 View Pathway
metabolic

Valine, Leucine, and Isoleucine Degradation

Bos taurus
Valine, isoleuciine, and leucine are essential amino acids and are identified as the branched-chain amino acids (BCAAs). The catabolism of all three amino acids starts in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with α-ketoglutarate as the amine acceptor. As a result, three different α-keto acids are produced and are oxidized using a common branched-chain α-keto acid dehydrogenase (BCKD), yielding the three different CoA derivatives. Isovaleryl-CoA is produced from leucine by these two reactions, alpha-methylbutyryl-CoA from isoleucine, and isobutyryl-CoA from valine. These acyl-CoA’s undergo dehydrogenation, catalyzed by three different but related enzymes, and the breakdown pathways then diverge. Leucine is ultimately converted into acetyl-CoA and acetoacetate; isoleucine into acetyl-CoA and succinyl-CoA; and valine into propionyl-CoA (and subsequently succinyl-CoA). Under fasting conditions, substantial amounts of all three amino acids are generated by protein breakdown. In muscle, the final products of leucine, isoleucine, and valine catabolism can be fully oxidized via the citric acid cycle; in the liver, they can be directed toward the synthesis of ketone bodies (acetoacetate and acetyl-CoA) and glucose (succinyl-CoA). Because isoleucine catabolism terminates with the production of acetyl-CoA and propionyl-CoA, it is both glucogenic and ketogenic. Because leucine gives rise to acetyl-CoA and acetoacetyl-CoA, it is classified as strictly ketogenic.

PW064671

Pw064671 View Pathway
metabolic

Valine, Leucine, and Isoleucine Degradation

Mus musculus
Valine, isoleuciine, and leucine are essential amino acids and are identified as the branched-chain amino acids (BCAAs). The catabolism of all three amino acids starts in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with α-ketoglutarate as the amine acceptor. As a result, three different α-keto acids are produced and are oxidized using a common branched-chain α-keto acid dehydrogenase (BCKD), yielding the three different CoA derivatives. Isovaleryl-CoA is produced from leucine by these two reactions, alpha-methylbutyryl-CoA from isoleucine, and isobutyryl-CoA from valine. These acyl-CoA’s undergo dehydrogenation, catalyzed by three different but related enzymes, and the breakdown pathways then diverge. Leucine is ultimately converted into acetyl-CoA and acetoacetate; isoleucine into acetyl-CoA and succinyl-CoA; and valine into propionyl-CoA (and subsequently succinyl-CoA). Under fasting conditions, substantial amounts of all three amino acids are generated by protein breakdown. In muscle, the final products of leucine, isoleucine, and valine catabolism can be fully oxidized via the citric acid cycle; in the liver, they can be directed toward the synthesis of ketone bodies (acetoacetate and acetyl-CoA) and glucose (succinyl-CoA). Because isoleucine catabolism terminates with the production of acetyl-CoA and propionyl-CoA, it is both glucogenic and ketogenic. Because leucine gives rise to acetyl-CoA and acetoacetyl-CoA, it is classified as strictly ketogenic.